REHOVOT, Israel, Feb. 22,
2024 /PRNewswire/ -- AgPlenus Ltd, a
global leader in designing and developing novel sustainable crop
protection products, and a subsidiary of Evogene Ltd. (Nasdaq:
EVGN) (TASE: EVGN), is pleased to announce the appointment of Dr.
Dan Jacob Gelvan as its new Chief
Executive Officer effective as of February
19, 2024.
Dr. Gelvan brings over three decades of extensive experience in
leading science and technology companies within the pharmaceutical,
biotech, and healthcare sectors. Dr. Gelvan has demonstrated
exceptional leadership and strategic vision in various companies,
ranging from pre-clinical stages through product launches. His
international exposure and ability to secure substantial funding
further emphasize his profound skills in multicultural
management.
In conjunction with Dr. Gelvan's appointment, Dr. Brian Ember,
AgPlenus' current CEO, will transition to the role of Chief
Business Officer. Brian's contributions have been invaluable to
AgPlenus' growth, and he will continue in fostering strategic
partnerships and drive business expansion.
Ofer Haviv, CEO of Evogene and
chairman of AgPlenus, said, "We are happy to welcome Dan to the
AgPlenus team. His extensive experience and proven track record
will position him to guide AgPlenus through its next phase of
growth and innovation. I would like to thank Brian for his
contribution and leadership to AgPlenus and I look forward to
continuing our work together in his new role as the company's
CBO."
Dr. Dan Jacob Gelvan
conveyed his excitement for his new role, stating, "I am honored to
join AgPlenus and lead the company in its mission to revolutionize
agriculture through sustainable crop protection solutions. I look
forward to collaborating with the talented team at AgPlenus to
drive innovation and create value for our stakeholders."
About AgPlenus Ltd.
AgPlenus is a platform company designing effective and
sustainable crop protection products. At AgPlenus, we are solving
pesticide resistance by infusing the discovery process with
predictive biology and artificial intelligence. AgPlenus
leverages the ChemPass AI tech-engine, licensed from
Evogene, to discover and bring to market effective and
sustainable crop protection products. Our target-based
approach allows us to reduce risk and increase efficiency, so that
we can deliver on our promise to defeat global pesticide
resistance. AgPlenus is a subsidiary of Evogene Ltd.
For more information, please visit www.agplenus.com.
About Evogene Ltd.:
Evogene (Nasdaq: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines -
MicroBoost AI, ChemPass
AI and GeneRator AI – leveraging Big Data
and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each
tech-engine is focused on the discovery and development of
products based on one of the following core components: microbes
(MicroBoost AI), small molecules (ChemPass AI), and
genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates",
"demonstrates" or words of similar meaning. For example, Evogene
and its subsidiaries are using forward-looking statements in this
press release when they discuss AgPlenus' growth and expansion and
its ability to revolutionize agriculture through sustainable crop
protection solutions. Such statements are based on current
expectations, estimates, projections and assumptions, describe
opinions about future events, involve certain risks and
uncertainties which are difficult to predict and are not guarantees
of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, the current war between Israel and Hamas and any worsening of the
situation in Israel such as
further mobilizations or escalation in the northern border of
Israel, and those risk factors
contained in Evogene's reports filed with the applicable securities
authority. In addition, Evogene and its subsidiaries rely, and
expect to continue to rely, on third parties to conduct certain
activities, such as their field-trials and pre-clinical studies,
and if these third parties do not successfully carry out their
contractual duties, comply with regulatory requirements or meet
expected deadlines, Evogene and its subsidiaries may experience
significant delays in the conduct of their activities. Evogene and
its subsidiaries disclaim any obligation or commitment to update
these forward-looking statements to reflect future events or
developments or changes in expectations, estimates, projections,
and assumptions.
Logo:
https://mma.prnewswire.com/media/1334691/AgPlenus_Logo.jpg
Logo: https://mma.prnewswire.com/media/1947468/Evogene_Logo.jpg
Evogene Investors' Contact:
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
+972-8-9311901
View original
content:https://www.prnewswire.com/news-releases/agplenus-announces-appointment-of-dr-dan-jacob-gelvan-as-its-incoming-chief-executive-officer-302068656.html
SOURCE AgPlenus Ltd.